Electra Therapeutics, a late clinical-stage biotech developing antibodies targeting signal regulatory proteins for immune-mediated diseases and cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Electra Therapeutics is developing a class of precision medicines directed at signal regulatory proteins (SIRP) expressed on specific immune cell populations. Lead candidate ipsoprubart is a pan-SIRP monoclonal antibody designed to selectively deplete pathological myeloid cells and T cells, currently in the registrational Phase 2/3 SURPASS trial for secondary hemophagocytic lymphohistiocytosis (sHLH); Phase 1b data showed a 100% eight-week overall survival rate and 100% overall response rate in 12 frontline malignancy-associated HLH patients. Ipsoprubart is also in a Phase 1 trial for relapsed/refractory T and NK cell malignancies. Second candidate ELA822, a SIRPγ-specific antibody for chronic T cell-mediated immune disorders, began a Phase 1 trial in Europe in August 2026.
The South San Francisco, CA-based company was founded in 2018 and plans to list on the Nasdaq under the symbol ETRA. Jefferies, TD Cowen, Evercore ISI, and Cantor are the joint bookrunners on the deal. No pricing terms were disclosed.
